

Special Issue

Development of Epitope-Based Peptide Vaccine

Message from the Guest Editors

This Special Issue focuses on the development of epitope-based peptide vaccines. Identification of immunodominant B- and T-cell epitopes is crucial to induce protective responses in the host upon vaccination. Moreover, immunoinformatics-based approaches, depending on in silico prediction of potential epitopes, may significantly reduce the time required to screen peptide libraries to discover immunodominant epitopes. Here, we are trying to shed light on the importance of epitope-based peptide vaccine strategies as alternative approaches, which may help to improve vaccine efficacy. This Special Issue of *Vaccines* aims to cover topics relevant to epitope-based peptide vaccine design. We are pleased to invite you to submit an original research or review article discussing this topic. We are looking forward to publishing your interesting inputs and original insights in this field of research.

Guest Editors

Prof. Dr. Maria Tempesta

Department of Veterinary Medicine, University Aldo Moro of Bari, Sp Casamassima Km 3, Valenzano, 70010 Bari, Italy

Dr. Heba Alzan

Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA 99164-7040, USA

Deadline for manuscript submissions

closed (31 May 2022)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/74962

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).